Phenotypes associated with this allele

• Allele Symbol: Cd180^tm1Kmiy
• Allele Name: targeted mutation 1, Kensuke Miyake
• Allele ID: MGI:3581654
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Cd180^tm1Kmiy/Cd180^tm1Kmiy	involves: 129P2/OlaHsd * C57BL/6	MGI:3582401
hm2	Cd180^tm1Kmiy/Cd180^tm1Kmiy	involves: 129P2/OlaHsd * C57BL/6 * NZB * NZW	MGI:3799682
cx3	Cd180^tm1Kmiy/Cd180^tm1Kmiy Fas^lpr/Fas^lpr	MRL.Cg-Cd180^tm1Kmiy Fas^lpr	MGI:3799683

Genotype
MGI:3582401

hm1

• Allelic Composition: Cd180^tm1Kmiy/Cd180^tm1Kmiy
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal humoral immune response ( J:63145 )

• impaired proliferative and humoral immune responses of B cells to lipopolysaccharides

decreased IgG2b level ( J:137066 )

• reduced in serum at 7 and 11 weeks of age

decreased IgG3 level ( J:137066 )

• significantly reduced in serum at 7 and 11 weeks of age

hematopoietic system

decreased IgG2b level ( J:137066 )

• reduced in serum at 7 and 11 weeks of age

decreased IgG3 level ( J:137066 )

• significantly reduced in serum at 7 and 11 weeks of age

Genotype
MGI:3799682

hm2

• Allelic Composition: Cd180^tm1Kmiy/Cd180^tm1Kmiy
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * NZB * NZW

immune system

decreased IgG2a level ( J:137066 )

• significantly lower in serum at 20 weeks than in Cd180^tm1Kmiy/+ heterozygous mice on this background

decreased IgG3 level ( J:137066 )

• significantly lower in serum at 20 weeks than in Cd180^tm1Kmiy/+ heterozygous mice on this background

hematopoietic system

decreased IgG2a level ( J:137066 )

• significantly lower in serum at 20 weeks than in Cd180^tm1Kmiy/+ heterozygous mice on this background

decreased IgG3 level ( J:137066 )

• significantly lower in serum at 20 weeks than in Cd180^tm1Kmiy/+ heterozygous mice on this background

Genotype
MGI:3799683

cx3

• Allelic Composition: Cd180^tm1Kmiy/Cd180^tm1Kmiy; Fas^lpr/Fas^lpr
• Genetic Background: MRL.Cg-Cd180^tm1Kmiy Fas^lpr

mortality/aging

mortality/aging ( J:137066 )

N • Cd180-deficiency ameliorates mortality in Fas^lpr mice; survival to >40 weeks is significantly greater than Fas^lpr homozygotes

hematopoietic system

hematopoietic system phenotype ( J:137066 )

N • numbers of CD4-positive T cells are rescued relative to MRL/MpJ-Fas^lpr

enlarged spleen ( J:137066 )

• severe in double mutants compared to controls, but reduced significantly from that observed in MRL/MpJ-Fas^lpr homozygotes

increased double-negative T cell number ( J:137066 )

• significantly increased relative to controls, similar to MRL/MpJ-Fas^lpr homozygotes

decreased B cell number ( J:137066 )

• CD44+ and CD69+ B cells in spleen are decreased relative to wild-type controls

decreased CD8-positive, alpha-beta T cell number ( J:137066 )

• reduced compared to wild-type controls, but higher than in MRL/MpJ-Fas^lpr homozygotes

decreased IgG2a level ( J:137066 )

• significantly lower in serum at 20 weeks than in MRL/MpJ-Fas^lpr single mutant mice

decreased IgG3 level ( J:137066 )

• significantly reduced in serum at 20 weeks than in MRL/MpJ-Fas^lpr single mutant mice

cardiovascular system

blood vessel inflammation ( J:137066 )

• necrotizing arteritis of small- and medium-sized arteries in kidneys is observed less frequently than in MRL/MpJ-Fas^lpr mice

renal/urinary system

glomerulonephritis ( J:137066 )

immune system

blood vessel inflammation ( J:137066 )

• necrotizing arteritis of small- and medium-sized arteries in kidneys is observed less frequently than in MRL/MpJ-Fas^lpr mice

enlarged spleen ( J:137066 )

• severe in double mutants compared to controls, but reduced significantly from that observed in MRL/MpJ-Fas^lpr homozygotes

increased double-negative T cell number ( J:137066 )

• significantly increased relative to controls, similar to MRL/MpJ-Fas^lpr homozygotes

decreased B cell number ( J:137066 )

• CD44+ and CD69+ B cells in spleen are decreased relative to wild-type controls

decreased CD8-positive, alpha-beta T cell number ( J:137066 )

• reduced compared to wild-type controls, but higher than in MRL/MpJ-Fas^lpr homozygotes

decreased IgG2a level ( J:137066 )

• significantly lower in serum at 20 weeks than in MRL/MpJ-Fas^lpr single mutant mice

decreased IgG3 level ( J:137066 )

• significantly reduced in serum at 20 weeks than in MRL/MpJ-Fas^lpr single mutant mice

enlarged lymph nodes ( J:137066 )

• severe compared to wild-type controls, but reduced significantly from that observed in MRL/MpJ-Fas^lpr homozygotes with largest difference in node size observed in axillary lymph nodes

increased autoantibody level ( J:137066 )

• autoantibody levels are much higher than wild-type controls but no difference is observed in IgG3 anti-IgG2a rheumatoid factor levels compared to MRL/MpJ-Fas^lpr homozygotes

increased anti-nuclear antigen antibody level ( J:137066 )

• levels of anti-dsDNA and anti-chromatin autoantibodies are elevated compared to wild-type, but are similar to MRL/MpJ-Fas^lpr homozygotes

glomerulonephritis ( J:137066 )

homeostasis/metabolism

abnormal blood urea nitrogen level ( J:137066 )

• levels are decreased with Cd180 deficiency, but are still elevated relative to wild-type controls

growth/size/body

enlarged spleen ( J:137066 )

• severe in double mutants compared to controls, but reduced significantly from that observed in MRL/MpJ-Fas^lpr homozygotes